AstraZeneca Strengthens Core Respiratory Business with US$1.15 B Pearl Therapeutics Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 3 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1960 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move that provides a much-needed boost to the company’s beleaguered late-stage pipeline, AstraZeneca has agreed to acquire Pearl Therapeutics, a US-based developer of combination therapies for chronic respiratory diseases, in a deal worth up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS